Monitor FDA meeting outcome for fasedienol's registrational pathway, as it will determine the company's clinical direction and capital needs. With cash only sufficient into 2027, a dilutive financing or partnership is likely within the next 12 months.
Drugs in focus
VTGN drug pipeline →fasedienol
▼ Bearish Named in this press release- Impact
- Phase
- Phase 3 (completed — two of three Phase 3 trials failed)
- Time to market
- Unknown — at least 3-5+ years if a new Phase 3 trial is required, with no guarantee of FDA acceptance of the proposed path
- Next catalyst
- None dated
What to watchFasedienol has now failed two consecutive Phase 3 trials (PALISADE-3 Dec 2025, PALISADE-4 June 2026). The stock traded at ~$2.04 before the PALISADE-4 miss and collapsed to ~$0.25, a ~$10M market cap. The company plans an FDA meeting for a potential new trial path, but the path to approval looks extremely long and uncertain. Watch for dilution risk as the company may need financing to fund any future trial.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 14 $0.2676entry
- T+1 · 3mo ago −2.84%α −2.37% · $0.2600
- T+5 · 3mo ago −8.82%α −7.45% · $0.2440
- T+20 · 2mo ago −9.12%α −7.13% · $0.2432
- T+60 · 8d ago −31.09%α −28.04% · $0.1844
Price Chart
How similar events traded
Executive Summary
Vistagen reported Q1 FY2027 results with a net loss of $0.30 per share, beating consensus of -$0.36 by 16.7%, and revenue of $1.48M (vs $0.17M consensus) driven by one-time sublicense recognition. Clinical updates were mixed: fasedienol's PALISADE-4 missed its primary endpoint but showed a signal in very severe SAD patients, with an FDA meeting planned. Cash of $31.7M funds operations into 2027 but not beyond a year, highlighting near-term financing risk.
Key Financial Metrics
Key Facts
- EPS of -$0.30 beat consensus -$0.36 by 16.7%
- Revenue of $1.48M beat $0.17M consensus, primarily from one-time sublicense recognition
- Net loss improved to $13.0M from $15.1M YoY
- Cash, equivalents, and marketable securities $31.7M; runway into 2027 but not beyond one year
- Fasedienol PALISADE-4 missed primary endpoint; post-hoc subgroup signal in very severe SAD
- FDA meeting planned for potential Phase 3 path forward for fasedienol
- Appointed new CMO and board member with neuroscience experience
Financial Impact
EPS beat of $0.06 (16.7%) and revenue beat of $1.31M (784%) on a one-time basis; net loss improved $2.1M YoY
Risk Factors
- Cash runway insufficient beyond one year; likely need for additional financing
- Fasedienol clinical program uncertain after PALISADE-4 miss; FDA may require additional trials
- No approved products; revenue is non-recurring and minimal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345334 |
Track record
21 reports on VTGN
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.40% at T+5 after the Jun 11, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.1843 Now $0.1800 −2.33% settles Nov 24
- Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.1805 Now $0.1800 −0.28% settles Nov 23
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
- Oct 30, 202617d ago 8-K Bearish 6/10 Entry $0.1675 to $0.1844 Now $0.1800 −7.46% ▼ −10.09% −10.01% vs SPY
- Oct 9, 20265w ago 8-K Neutral 3/10 Entry $0.2300 to $0.2000 Now $0.1800 −21.74% ▼ −13.04% −11.55% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $0.2700 to $0.2800 Now $0.1800 −33.33% ▲ +3.70% +3.93% vs SPY
- Sep 24, 20267w ago 8-K Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
- Sep 24, 20267w ago Press Release Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers